Target intelligence / Profile preview

Bilirubin

Molecular classification
Other (endogenous metabolite), Linear tetrapyrrole compound, Heme catabolism product
01

Overview

Bilirubin is an orange-yellow linear tetrapyrrole compound produced during normal breakdown of heme from senescent red blood cells. Heme degradation occurs primarily via macrophages where heme oxygenase converts heme into biliverdin which is then reduced to unconjugated (indirect) bilirubin by biliverdin reductase. Unconjugated bilirubin circulates bound tightly to albumin due to its hydrophobicity until taken up by hepatocytes where it undergoes conjugation with glucuronic acid via UDP-glucuronosyltransferase making it water-soluble ("direct"/conjugated). Conjugated bilirubin enters bile and ultimately reaches the intestine where bacterial enzymes further metabolize it into urobilinogen/stercobilinogen which are excreted through feces or urine after partial reabsorption. Clinically significant elevations occur when production exceeds hepatic clearance capacity—as seen with hemolysis—or when hepatic uptake/conjugation/excretion pathways are impaired—as seen with liver diseases or genetic disorders affecting conjugating enzymes. Elevated serum/plasma total and fractioned (direct/indirect) bilirubins serve as key diagnostic markers for jaundice etiology evaluation across all ages. While some studies suggest mild hyperbilirubinemia may confer antioxidant benefits under certain conditions without underlying liver pathology, excessive accumulation—particularly unbound/unconjugated form—is highly toxic especially during early brain development leading potentially irreversible neurological damage if untreated. Treatment strategies focus on enhancing elimination rather than directly inhibiting/binding the molecule.

Other names
Hematoidin(Z,Z)-Bilirubin IXa21H-Biline-8,12-dipropanoic acid8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dioneBilirubin (α)
02

Mechanism of action

Not applicable—no drugs act on bilirubin as their primary mechanism. Phototherapy acts physically by converting unconjugated bilirubin into excretable forms via light-induced structural changes rather than biochemical targeting of the molecule itself.

03

Biological functions

Waste product of heme metabolismAntioxidant properties in plasma at physiological concentrations
04

Disease associations

Jaundice/hyperbilirubinemia (marker and mediator)Liver dysfunction/liver disease biomarkerNeonatal neurotoxicity risk at high levels ("kernicterus")
05

Safety considerations

Neurotoxicity at high levels, especially unconjugated form crossing blood-brain barrier in neonates ("kernicterus")Risks associated with therapeutic interventions like phototherapy (e.g., dehydration, skin injury) and exchange transfusion (procedural risks)Increased free toxic fraction due to drug displacement interactions
06

Interacting drugs

Phototherapy (converts bilirubin into excretable forms)

1 more in the full profile.

07

Biomarkers

Total serum/plasma bilirubin level (TSB)Direct/conjugated vs indirect/unconjugated bilirubin fractionsUsed in Bhutani nomogram for neonatal jaundice risk assessmentComponent of MELD score for liver transplant prioritization

Beyond the preview

Go deeper on Bilirubin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bilirubin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call